Steven Quay, a pharmaceutical executive and author who has argued that COVID-19 originated in a Chinese laboratory, is in the final vetting stages to lead the National Institute of Allergy and Infectious Diseases (NIAID). Two sources, including a senior Department of Health and Human Services (HHS) official, confirmed to POLITICO that Health Secretary Robert F. Kennedy Jr. selected Quay for the role. The position, formerly held by Anthony Fauci, oversees a research budget of approximately $6.5 billion.
The selection follows a period of leadership turnover at the NIAID, which has been led by acting directors since Kennedy dismissed Director Jeanne Marrazzo last year. Marrazzo, who succeeded Fauci in 2023, has filed a federal lawsuit alleging her termination was retaliation for her internal complaints regarding vaccine policy and foreign research collaborations. While the National Institutes of Health (NIH) initially did not advance Quay to the interview stage during an open call for applicants last year, the agency approved his hiring last week following Kennedy's selection.
Quay, a physician and pathologist, has published two books detailing his belief that the COVID-19 genome reveals a laboratory origin. In 2024 Senate testimony, he alleged that some virologists committed "academic fraud" by making public statements about the virus's origins that he claimed were inconsistent with their private views. Quay has proposed new oversight measures for high-risk research, including the use of "watermarks" to trace engineered pathogens and the establishment of third-party review panels.
For the American public and the scientific community, the change marks a departure from historical agency norms. Quay would be the first NIAID director to arrive directly from the pharmaceutical industry rather than from government or academia, and he lacks formal training in infectious diseases. The shift in leadership comes as HHS has already taken steps to halt high-risk "gain-of-function" research—experiments that increase the transmissibility or lethality of a virus to study its behavior—and as some U.S. agencies, including the CIA and FBI, have signaled they lean toward the lab-leak theory.
The appointment does not require Senate confirmation, meaning Quay could assume control of the agency's research agenda and its thousands of employees as soon as final vetting is complete. His leadership will likely influence ongoing debates regarding federal oversight of research organizations like the EcoHealth Alliance, which had its funding suspended by HHS in 2024. While the World Health Organization and many virologists continue to maintain that a natural spillover from animals is the most likely origin of COVID-19, Quay’s new role gives an official platform to the laboratory-origin theory within the nation's primary infectious disease research body.
Quay has not yet commented on the selection, and HHS spokespeople did not respond to requests for comment. John Powers III currently serves as the acting director of the agency. A specific start date for Quay has not been reported.